Transcode Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Transcode Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $5.81 million for the year ending 2024.

  • Transcode Therapeutics, Inc. showed an increase of +110.0% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
  • This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
  • XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 601.8%.
  • Historical annual values: Fiscal year 2024: $5.81 million | Fiscal year 2023: $2.77 million | Fiscal year 2022: $4.97 million | Fiscal year 2021: $20.83 million | Fiscal year 2020: $828.0 thousand.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: